Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 46Recruiting 16Active not recruiting 12Terminated 10Withdrawn 4Unknown 3

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Lymphoma 10Lymphoma, Large B-Cell, Diffuse 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Follicular 5Burkitt Lymphoma 4Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Sarcoma 2Retinoblastoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large-Cell, Anaplastic 2Immunoblastic Lymphadenopathy 2Dendritic Cell Sarcoma, Interdigitating 2Central Nervous System Neoplasms 2Waldenstrom Macroglobulinemia 1Vomiting 1Sezary Syndrome 1Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nausea 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Primary Effusion 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Cyclophosphamide 11fludarabine phosphate 10Rituximab 6Peripheral Blood Stem Cell Transplantation 6Cytarabine 6fludarabine 5Vincristine 4Radiotherapy 4Etoposide 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Filgrastim 3tisagenlecleucel 2blinatumomab 2Vorinostat 2Prednisone 2Pentetic Acid 2Methylprednisolone 2Melphalan 2Drug Therapy 2Doxorubicin 2Cord Blood Stem Cell Transplantation 2Carmustine 2CT-P10 2Busulfan 2Bortezomib 2Biopsy 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Burkitt Lymphoma × Vincristine × Clear all
NCT04448834 2022-03-02

Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL

Duke University

Phase 2 Withdrawn
Lymphoid

Burkitt Lymphoma

NCT03851081 2022-01-28

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Roswell Park Cancer Institute

Phase 1/2 Withdrawn
Lymphoid

Burkitt Lymphoma

NCT02538926 2018-11-14

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

University of Washington

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00004039 2015-08-19

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Hoag Memorial Hospital Presbyterian

Phase 2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡